- Home
- DHAI vs NERV Comparison
DHAI vs NERV Comparison
Compare DHAI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- NERV
- Stock Information
- Founded
- DHAI 2007
- NERV 2007
- Country
- DHAI United States
- NERV United States
- Employees
- DHAI N/A
- NERV N/A
- Industry
- DHAI
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- NERV Health Care
- Exchange
- DHAI NYSE
- NERV Nasdaq
- Market Cap
- DHAI 11.6M
- NERV 12.0M
- IPO Year
- DHAI N/A
- NERV 2014
- Fundamental
- Price
- DHAI $0.27
- NERV $2.13
- Analyst Decision
- DHAI
- NERV Hold
- Analyst Count
- DHAI 0
- NERV 1
- Target Price
- DHAI N/A
- NERV $5.00
- AVG Volume (30 Days)
- DHAI 2.6M
- NERV 20.2K
- Earning Date
- DHAI 08-18-2025
- NERV 08-05-2025
- Dividend Yield
- DHAI N/A
- NERV N/A
- EPS Growth
- DHAI N/A
- NERV N/A
- EPS
- DHAI N/A
- NERV 0.83
- Revenue
- DHAI $69,573,000.00
- NERV N/A
- Revenue This Year
- DHAI N/A
- NERV N/A
- Revenue Next Year
- DHAI N/A
- NERV N/A
- P/E Ratio
- DHAI N/A
- NERV $2.61
- Revenue Growth
- DHAI 5.40
- NERV N/A
- 52 Week Low
- DHAI $0.12
- NERV $1.15
- 52 Week High
- DHAI $3.25
- NERV $3.30
- Technical
- Relative Strength Index (RSI)
- DHAI 53.70
- NERV 66.09
- Support Level
- DHAI $0.24
- NERV $1.94
- Resistance Level
- DHAI $0.31
- NERV $2.32
- Average True Range (ATR)
- DHAI 0.03
- NERV 0.15
- MACD
- DHAI 0.00
- NERV 0.03
- Stochastic Oscillator
- DHAI 50.63
- NERV 73.38
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.